Digital Gout Care Model Boosts Urate Control
A 12-month randomized trial in 280 men found a physician-supervised app-led program improved serum urate target attainment and reduced flares.
Updated on Nov. 10, 2026 in Arthritis
Live Poll
Would you trust a doctor-supervised app to manage a chronic condition like gout?
A 12-month randomized controlled trial, published November 4, 2026, in Arthritis & Rheumatology, found that a physician-supervised, digitally supported gout care model achieved serum urate below 360 μmol/L in 85.0 percent of participants versus 48.6 percent under usual care. The model also lowered annualized gout flare frequency to 0.02 flares per year compared with 0.10 under usual care.
Why it matters
Gout is a common form of inflammatory arthritis, and many patients fail to reach target urate levels under standard care. The results suggest structured digital support paired with physician oversight may help close that treatment gap, with adverse event rates comparable between groups.
The trial enrolled 280 men with gout, split evenly at 140 per arm, with 85.0 percent of the App-Led Care group reaching serum urate below 360 μmol/L versus 48.6 percent of usual care (risk ratio 1.75). Its single-center, open-label design and 12-month duration leave longer-term effects and generalizability to other populations unresolved.
The players
Tongji University School of Medicine
A medical school in Shanghai, China, affiliated with Tongji University, which conducted the randomized trial of the digitally supported gout care model.
Arthritis & Rheumatology
A peer-reviewed medical journal published by the American College of Rheumatology that carries original research in rheumatology and musculoskeletal disease.
The details
Researchers at Tongji University School of Medicine in Shanghai randomized men with gout to the 1CARE platform or usual care. The App-Led Care model combined automated behavioral reminders, tiered education, remote serum urate monitoring, and weekly physician review under a treat-to-target approach.
Timeline
November 4, 2026: Study published online in Arthritis & Rheumatology.
12 months: Trial duration and primary outcome measurement period.
Health Landscape
The trial applies the treat-to-target approach embedded in American College of Rheumatology gout guidelines, asking whether digital tools can deliver those urate goals at scale. Long-standing gaps between recommended and achieved urate control make the 85.0 percent target attainment a notable benchmark against usual care's 48.6 percent.
Men with gout who struggle to keep urate levels in range may find that structured remote monitoring and regular physician review improves control and reduces painful flares. The trial reported comparable adverse event rates between groups, though whether such programs are available outside study settings remains unclear.
The takeaway
Consistent urate monitoring paired with ongoing clinical feedback may be the most practical lever for people with gout. Patients should discuss target urate levels and flare history with their clinicians rather than relying on symptom relief alone.
Further reading
Explore more on Arthritis to see how urate control fits into broader joint disease management.
Source note: This article includes information reported by Healthday.
Live Poll
Would you trust a doctor-supervised app to manage a chronic condition like gout?
